Enliven Therapeutics, Inc. (ELVN) Stock Ticker
ELVN right now
Market factors today
Unlock the full ELVN picture
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN stock facts
| Ticker symbol | ELVN |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $3.2B |
| CEO | Richard A. Fair |
| Employees | 67 |
| Headquarters | Boulder, CO, US |
| IPO date | 2020-03-12 |
| Website | www.enliventherapeutics.com |
What you can see for ELVN on Tickr
Live ELVN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ELVN report.
Rankings
FAQ
What is the ticker symbol for Enliven Therapeutics, Inc.?
The ticker symbol for Enliven Therapeutics, Inc. is ELVN, listed on the NASDAQ Global Select.
What is ELVN?
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also…